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SummAry – Our aim was to assess the clinical course and outcome of AnCA-positive, pauci-
immune renal limited vasculitis, their correlation with laboratory and histopathologic parameters 
recorded at initial and follow up testing, and to identify the possible outcome predictors. The study 
included 17 patients with renal biopsy, clinical, serologic and histopathologic parameters meeting 
the criteria for pauci-immune AnCA-positive glomerulonephritis without extrarenal manifestati-
ons of the disease. Creatinine clearance, 24-hour proteinuria and AnCA titer by eliSA method 
were determined at disease onset, during treatment and at the end of follow up. in 15 patients, the 
diagnosis was verified by kidney biopsy. data were processed by Spearman correlation coefficient 
and mann-Whitney test, and survival by Kaplan-meier test. lower percentage of glomeruli affected 
with vasculitis, better initial renal function as measured by serum creatinine or creatinine clearance, 
and lower chronicity on biopsy were identified as favorable indicators of kidney function outcome. 
Therapy responders had highest initial and lowest final 24-h proteinuria. The highest level of final 
24-h proteinuria was recorded in dialysis dependent patients. The cumulative one-year and two-year 
patient and kidney survival rate was 64% and 50%, and 64% and 38%, respectively. 
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Introduction
vasculitis is an inflammation of the vascular wall 
as an immune response to a number of antigens that 
are very rarely detected. Based on Chapel-Hill’s con-
sensus definition, vasculitides are classified into three 
groups according to the size of blood vessels involved1. 
vasculitides with the presence of antineutrophil cyto-
plasmic antibodies (AnCA) have subsequently been 
singled out from group 3 vasculitides. This group 
includes microscopic polyangiitis, Wegener’s granu-
lomatosis, Churg-Strauss syndrome, and a variant 
of AnCA renal vasculitis, named AnCA-associat-
ed vasculitis2-4. renal involvement is frequently ob-
served.
The annual incidence of AnCA-associated vascu-
litis is 20 per million population2-4. The prognosis was 
very poor before the advent of immunosuppressant 
therapy; 80% of patients died in the first year. With 
the introduction of immunosuppressants, this fatal 
disease has turned to a relapsing disease with 60%-
80% 5-year patient survival2-7. renal involvement de-
velops with time in 50%-85% of patients3,8. The rate of 
two-year kidney survival is only 64%-75%9. 
Some AnCA-associated vasculitides are exclu-
sively limited to the kidneys. At the time of biopsy, 
some grade of extracapillary proliferation is seen in 
more than 50% of these patients. The presence of both 
acute and chronic glomerular and renal interstitial le-
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sions is quite frequently observed, indicating numer-
ous exacerbations2,7,9,10. 
to our knowledge, there is no literature report 
on the study of prognostic factors in pauci-immune 
glomerulonephritis without extrarenal manifesta-
tions7. The aim of the present study performed in a 
relatively small group of patients was to assess the 
clinical course and outcome of AnCA-positive renal 
vasculitis, and correlation between the disease out-
come and initial parameters of this type of vasculitis, 
including AnCA-antibodies, serum creatinine, crea-
tinine clearance, 24-hour proteinuria and renal biopsy 
histology, with the same treatment protocol.
Patients and Methods
The study included 17 patients with pauci-immune 
AnCA-positive renal vasculitis. none of the patients 
had any extrarenal manifestations. Clinical diagnosis 
was based on the finding of nephritic urinary sedi-
ment and progressing renal failure. The diagnosis was 
verified by the finding of elevated AnCA titer (nega-
tive AnCA finding did not rule the disease out when 
it was demonstrated on renal biopsy11) and renal bi-
opsy. The titer of AnCA antibodies was determined 
by eliSA at three time points (initially, t1; during 
immunosuppressant therapy, t2; and at the end of fol-
low up, t3). Serum creatinine and creatinine clearance 
were also determined at these time points, whereas 
24-hour proteinuria was measured immediately be-
fore therapy initiation and at the end of follow up. re-
nal biopsy was performed in 15 of 17 study patients. 
Patients were divided into three groups according to 
the percentage of vasculitis-affected glomeruli de-
tected on microscopy: 25%-50%, 50%-75% and >75% 
of glomeruli involved. Histologic features were used 
to assess the disease activity (fibrinoid necrosis, cel-
lular and fibrocellular extracapillary and intracapillary 
proliferates, interstitial edema, cellular infiltration of 
renal interstitium, and tubular necrosis) and chronic-
ity (glomerular sclerosis, fibrous crescents, Bowman 
capsule adhesions, interstitial fibrosis and tubular at-
rophy). disease activity and chronicity were expressed 
as mild (+), moderate (++) or pronounced (+++). 
All patients except one (dropout from follow 
up) were treated with prednisolone and cyclophos-
phamide. They were initially administered methyl-
prednisolone as bolus infusion, 15 mg/kg body weight 
(b.w.) over three days, then oral prednisolone, 1 mg/
kg b.w. daily, tapered to 0.4 mg/kg b.w. daily at the 
end of the first month and to 0.25 mg/kg b.w. daily 
at the end of the second month of treatment. Cyclo-
phosphamide was administered as intravenous (i.v.) 
infusion in a single dose of 500 mg/m2 body surface 
area every four weeks (n=12), or as a continuous oral 
dose of 2 mg/kg b.w. daily until remission (n=4). in 
patients older than 65, the dose was reduced by 20%, 
and in those with creatinine clearance below 10 ml/
min by 50%. upon remission, the treatment was con-
tinued with corticosteroids in a dose of 5 mg/day, in 
combination with azathioprine or mycophenolate 
mofetil, or with cyclophosphamide until completion 
of 12-month period. Plasmapheresis was performed 
instead of methyl-prednisolone boluses when the pa-
tient presented with serum creatinine higher than 500 
µmol/l or was dependent on dialysis and without sig-
nificant chronicity on renal biopsy, expecting better 
renal survival12,13. We had four patients treated with 
plasmapheresis. none of them recovered renal func-
tion (sample too small for statistical analysis). There 
was no between-group difference in patient survival 
and rate of severe adverse events. 
According to therapeutic response, patients were 
classified into four groups: group 1, patients that 
achieved remission (r), i.e. significant improvement 
of renal function with significant reduction of 24-
hour proteinuria and erythrocyturia; group 2, patients 
with partial remission, i.e. further deterioration of 
renal function was prevented, however, without its 
improvement; group 3, patients that failed to respond 
to therapy (no remission), i.e. initially dialysis depen-
dent patients in which therapy failed to improve their 
renal function; and group 4, patients with or without 
disease relapse that developed end-stage renal disease 
(eSrd). disease relapse was determined by serum 
creatinine increase by more than 30% between two 
consecutive measurements.
immunosuppressant side effects were classified 
into five categories: 0, no side effects; 1, mild side ef-
fects; 2, moderate side effects; 3, serious side effects; 
and 4, death due to side effects.
Spearman correlation coefficient was used to deter-
mine correlations among selected variables, whereas 
between-group distribution differences were assessed 
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by mann-Whitney exact test. As the study popula-
tion was rather small, statistical analysis was not per-
formed, only tables of contingency were employed. 
Patient and kidney survival was assessed by Kaplan-
meier test. Statistical significance was set at 1% and 
5% (p<0.01 and p<0.05)14,15.
Results
The study included 17 patients (nine female and 
eight male) with AnCA-positive renal vasculitis, 
mean age at study entry 67.10±9.58 years, mean fol-
low up 7.50±8.95 months, and mean duration of 
prodromal symptoms 6.00±9.58 months as assessed 
from their history data. The mean serum creatinine 
level was 350±320 µmol/l at disease onset, 513±316 
µmol/l at initiation of immunosuppressant therapy, 
and 407±304 µmol/l at the end of follow up. The 
mean daily proteinuria was 2533±1894 mg at therapy 
introduction and 1406±1919 mg at the end of follow 
up.
elevated AnCA antibody titer as determined by 
eliSA was recorded in 13 (76.47%) patients (mPO-
AnCA), with the following mean values recorded at 
three time points: t1=68±45 u/l, t2=23±19 u/l and 
t3=12±11 u/l (table 1).
renal biopsy was performed in 15 of 17 study pa-
tients; 25%-50% glomerular involvement with vascu-
litis was recorded in three (20%), 50%-75% involve-
ment in five (33.33%) and >75% involvement in seven 
(46.67%) patients, i.e. almost half of patients under-
going renal biopsy (table 2). 
disease activity as assessed from renal biopsy histol-
ogy was mild in six, moderate in five and severe in four 
patients with renal biopsy. The signs of mild, moderate 
and serious disease chronicity were recorded in three, 
four and eight patients, respectively (table 2).
Five patients treated with corticosteroids and cy-
clophosphamide died, four of them due to complica-
tions of immunosuppressant therapy (most frequently 
0 = initial value; 1 = value measured at therapy initiation; 2 = value measured at the end of follow up
Table 1. patient laboratory data
variable n mean ±Sd minimum maximum
Serum creatinine0 (µmol/l) 17 349.5 320.2 94.0 1112.0
Serum creatinine1 (µmol/l) 17 513.0 315.6 155.0 1100.0
Serum creatinine2 (µmol/l) 16 406.8 303.6 110.0 1110.0
Creatinine clearance0 (ml/s) 17 0.5 0.4 0.1 1.1
Creatinine clearance1 (ml/s) 16 0.4 0.3 0.1 0.9
Creatinine clearance2 (ml/s) 16 0.5 0.3 0.1 1.0
Proteinuria1 (mg/24 h) 17 2533.2 1893.8 800.0 6926.0
Proteinuria2 (mg/24 h) 16 1406.4 1919.2 227.5 8015.0
mPO-AnCA titer1 (u/ml) 13 68.0 44.9 10.1 158.0
mPO-AnCA titer2 (u/ml) 8 22.6 18.5 4.5 51.0
mPO-AnCA titer3 (u/ml) 11 12.2 10.6 1.1 27.4
Table 2. Results of renal biopsy
variable n Percentage
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from respiratory infection and respiratory failure). 
Another five patients developed eSrd. two of these 
patients were dialysis dependent at study entry and 
none recovered renal function in spite of treatment. 
remission was observed in only three patients and 
partial remission in four patients. Spearman correla-
tion coefficient showed negative correlation between 
older age and creatinine clearance at the beginning 
(r=0.605, p=0.012) but not at the end of follow up 
(table 3). As expected, these patients received low-
er doses of cyclophosphamide, AnCA titer showed 
negative correlation with cyclophosphamide dosage 
during (r=0.761, p=0.027) and at the end (r=0.646, 
p=0.043) of treatment. A positive, statistically sig-
nificant correlation was found between final AnCA 
titer and percentage of vasculitis affected glomeruli 
(r=0.684, p=0.029), between initial and final serum 
creatinine levels (r=0.582, p=0.017), and between 
percentage of vasculitis affected glomeruli and serum 
creatinine (measured initially and at introduction of 
immunosuppressant therapy vs. end of follow up). in-
terestingly, the highest correlation was recorded be-
tween the percentage of vasculitis affected glomeruli 
and serum creatinine measured at the end of follow up 
(r=0.767, p=0.001). negative correlation was found 
between disease activity and chronicity (r=0.869, 
p=0.00003), and positive correlation between disease 
chronicity and serum creatinine (Fig. 1).
Analysis of patient subgroups according to out-
come (table 4) showed that there were no significant 
differences according to age and AnCA titer mea-
sured initially or during treatment. Patients with re-
mission had a higher initial AnCA titer; however, the 
difference did not reach statistical significance. These 
patients had lowest final AnCA titer; yet, statistically 
significant difference was only recorded between the 
subgroups with lethal outcome and dialysis patients. 
Fig. 1. Correlation between the degree of chronicity on 
renal biopsy and final values of serum creatinine. Chro-
nicity is expressed semiquantitatively according to degree 
1-3. Testing was performed using Spearman coefficient 
correlation.
Table 3. Significance between selected pairs of study variables
Pairs of variables n R* p-level
Age : Cr.cl.1 ** (mL/s) 17 –0.494 0.04
Age : Cr.cl.2 ** (mL/s) 16 –0.606 0.01
Age : cyclophosphamide dose 16 –0.541 0.03
Cr.cl.1 (mL/s) : Cr.cl.2 16 0.812 0.0001
Cr.cl.1 (mL/s) : Cr.cl3** 15 0.654 0.01
Cr.cl.2 (mL/s) : Cr.cl.3 15 0.605 0.012
Cr.cl.1 (mL/s) : proteinuria 2 15 –0.581 0.018
Percentage of affected glom. : ser. creatinine1 (µmol/L) 15 0.532 0.041
Percentage of affected glom. : ser. creatinine2 (µmol/L) 15 0.645 0.009
Percentage of affected glom. : ser. creatinine3 (µmol/L) 15 0.767 0.001
Percentage of affected glom. : MPO-anca titer3 15 0.684 0.029
Activity : chronicity 15 –0.869 0.00003
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Patients with disease remission showed highest initial 
creatinine clearance in comparison to the deceased 
and dialysis patients. Final creatinine clearance was 
significantly higher in patients with remission than in 
dialysis patients and those with partial remission but 
not those with lethal outcome. The latter subgroup 
of patients received the highest dose of cyclophosph-
amide. Patients with disease remission had highest 
initial and lowest final daily proteinuria. At the end 
of follow up, highest proteinuria was measured in di-
alysis patients.
Three relapses recorded in two patients occurred 
upon discontinuation of immunosuppressant therapy 
and were accompanied by an increase in the titer of 
mPO-AnCA autoantibodies. none of the patients 
with disease remission had >75% of glomeruli involved 
with vasculitis and pronounced signs of chronic dis-
ease. All dialysis patients showed >50% of glomeruli 
Fig. 2. Kaplan-Meier analysis of patient survival after 
diagnosis.
Table 4. Outcome analysis according to patient subgroups
Outcome death responders dialysis dependent (non-responders)
Partial responders 
(CrF) p-level
(1) (2) (3) (4)
mean ±Sd mean ±Sd mean ±Sd mean ±Sd
Age (yrs) 71.60 5.60 65.67 2.52 63.40 12.90 67.25 12.79
mPO-anca titer1
(u/l) 53.98 38.24 118.10 56.43 78.17 55.07 47.83 27.72
mPO-anca titer2
(u/l) 20.93 12.24 4.50 0.00 28.35 32.03 28.35 24.25
mPO-anca titer3
(u/l) 7.43 9.95 2.05 1.20 22.57 2.52 13.20 12.30
p1:3=0.100
Cr.cl.0 (ml/s) 0.52 0.26 0.73 0.24 0.34 0.34 0.53 0.54
Cr.cl.1 (ml/s) 0.27 0.10 0.74 0.21 0.22 0.19 0.50 0.44
p1:2=0.057
p2:3=0.071












dose (mg/day) 90.33 82.74 32.80 2.83 16.88 10.05 28.75 25.66
p1:3=0.063     
p2:3=0.095
Cyclophosphamide 
dose (mg/kg/day) 0.48 0.35 0.68 0.54 0.34 0.10 0.38 0.07
















Survival time after diagnosis (months)
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n % n % n % n %
Percentage of affected glomeruli
25%-50% 1 6.7 2 13.3 0 0.0 0 0.0
50%-75% 1 6.7 1 6.7 1 6.7 2 13.3
>75% 1 6.7 0 0.0 4 26.7 2 13.3
Chronicity
mild 1 6.7 2 13.3 0 0.0 0 0.0
moderate 1 6.7 1 6.7 2 13.3 0 0.0
Severe 1 6.7 0 0.0 3 20.0 4 26.7
Activity
mild 1 6.7 0 0.0 3 20.0 2 13.3
moderate 0 0.0 1 6.7 2 13.3 2 13.3
Severe 2 13.3 2 13.3 0 0.0 0 0.0
*sample size too small for statistical testing; CRF = chronic renal failure
affected with vasculitis, moderate to severe chronic le-
sions on renal biopsy, and mild to moderate vasculitis 
activity (table 5).
One-year and two-year cumulative patient sur-
vival rate was 64% and only 50%, respectively (Fig. 2). 
The respective figures for kidney survival were 64% 
and only 38% (Fig. 3).
Discussion
in the present study, an attempt was made to find 
possible correlations between some parameters of 
pauci-immune AnCA-positive renal limited vasculi-
tis and origin of the disease in patients treated with 
the same immunosuppressive protocol. The patient 
group was small, thus the conclusions should not be 
considered definitive.
in our study, patients with disease remission ini-
tially had highest titer of AnCA autoantibodies, 
creatinine clearance and 24-h proteinuria. Their re-
nal biopsy specimens showed least pronounced signs 
of chronicity and most pronounced signs of disease 
activity, with no case of >75% glomerular vasculitis 
involvement. non-responders showed highest per-
centage of glomerular vasculitis involvement with 
moderate to severe chronicity, without signs of severe 
disease activity. 
A number of studies investigated clinical16,17, se-
rologic8,9 and histopathologic parameters10,16-19 as 
prognostic indicators of patient and kidney survival 
in AnCA-associated vasculitis (but as part of clinical 
syndrome like polyangiitis and Wegener’s granuloma-
tosis). in AnCA-positive systemic vasculitis, pulmo-
nary hemorrhage4,17, advanced age3,6,8,17,20, rate of renal 
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disease relapses3,9,11,20, elevated initial serum creati-
nine level4,6,11,17,21 and infections as a consequence of 
immunosuppressive therapy6,8,9 were found to be most 
important indicators of patient survival. The higher 
the initial serum creatinine, the higher was the risk of 
eSrd development3,4,6-9,21. The chronic nature of le-
sions was another unfavorable predictor of poor renal 
function outcome6,18,19. The percentage of glomeruli 
not affected with vasculitis was the major histopatho-
logic predictor of favorable outcome18,19,21,22.
in our study, chronicity and elevated initial serum 
creatinine were also found to predict unfavorable renal 
outcome, whereas no such role was observed for dis-
ease activity. none of the patients with active lesions 
detected in kidney biopsy specimens achieved remis-
sion, and none of those with pronounced chronicity 
achieved complete remission.
in some studies, disease activity was a predictor 
of favorable outcome, supporting the hypothesis that 
vasculitis can be at least in part reversible if timely 
diagnosed and treated11,21,23. Other studies, however, 
did not confirm this concept17,22. maybe there is a crit-
ical point in lesion progression when recovery is not 
possible anymore, and which can only lead to chronic 
irreversible changes17,22,23. it should be noted that in 
our study patients with remission had higher initial 
and significantly lower final proteinuria as compared 
to patients with partial remission and those with le-
thal outcome. At the end of follow up, patients with 
remission also had significantly lower proteinuria than 
dialysis patients. Franssen et al.24 demonstrated that 
proteinuria in mPO-AnCA positive patients was an 
unfavorable marker of renal function. neumann et 
al.25 found positive correlation between proteinuria at 
diagnosis and chronicity on repeated kidney biopsy, 
both being significant unfavorable indicators of late 
renal function. Our dialysis patients showed higher 
proteinuria at the end of follow up than those with re-
mission, which may have been due to discontinuation 
of immunosuppressive therapy. 
AnCA-positive, mostly mPO-AnCA positive, 
pauci-immune glomerulonephritis of microscopic 
polyangiitis and renal vasculitis may frequently prog-
ress to eSrd, even without relapse7,18,24. These varia-
tions may be of paramount importance for the choice 
of cyclophosphamide therapy. Pulsed dosage is pre-
ferred in the management of renal limited vasculitis, 
and continuous therapy for Wegener’s granulomato-
sis25. Cohen et al.20 report on 22 patients with renal 
vasculitis included in their study group to have had 
higher initial serum creatinine levels than other pa-
tients.
The proportion of seronegative patients was com-
parable to the results described by other authors, 
ranging from 7% to 23%. mortality rate was quite 
high in our patients, which was attributable to the 
complications of immunosuppressive therapy, infec-
tions in particular, as also emphasized elsewhere2,4,6,7. 
in addition, there were a high proportion of dialysis 
patients, probably due to chronic renal lesions that 
had failed to be recognized on time because of their 
scanty clinical picture, thus only relying on pathologic 
urine finding10.
in conclusion, based on our own results and litera-
ture data, we are inclined to describe pauci-immune 
AnCA-positive renal vasculitis as a rare disease pre-
senting with a clinical picture of rapidly progressing 
glomerulonephritis; however, it may frequently prog-
ress slowly, with gradual aggravation of renal function. 
The symptomatology is scanty, thus the diagnosis is 
late, and histopathologic signs of chronicity on kidney 
biopsy are more common than the signs of disease ac-
tivity. The course of the disease is by no means benign. 
it is a disease of advanced age and mortality rate is 
high due to immunosuppressive therapy.
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Sažetak
KliniČKi tiJeK i POKAZAtelJi iSHOdA AnCA-POZitivnOG PAuCi-imunOG nA BuBreGe 
OGrAniČenOG vASKulitiSA
V. Rupčić, M. Jakić, V. Rupčić, V. Vizjak i M. Fijačko 
Cilj rada bio je procijeniti klinički tijek i ishod AnCA-pozitivnog pauci-imunog na bubrege ograničenog vaskulitisa, 
njihovu korelaciju s laboratorijskim i histopatološkim parametrima zabilježenim na početku praćenja te tijekom liječenja, 
kako bi se utvrdili mogući pokazatelji ishoda tijeka bolesti. u ispitivanje je bilo uključeno 17 bolesnika s biopsijskim, kli-
ničkim i histopatološkim parametrima, koji su ispunjavali kriterije za dijagnozu pauci-imunog AnCA-pozitivnog glome-
rulonefritisa bez izvanbubrežnih manifestacija bolesti. na početku praćenja, tijekom liječenja te na kraju razdoblja praćenja 
određivali su se klirens kreatinina (ml/s), 24-satna proteinurija, a u 15 bolesnika učinjena je biopsija bubrega. Podaci su 
obrađeni Spearmanovim koeficijentom korelacije, mann-Whitneyjevim testom, a preživljavanje Kaplan-meireovim te-
stom. manji postotak zahvaćenosti glomerula, bolja početna bubrežna funkcija mjerena serumskim kreatininom ili kliren-
som kreatinina te slabije izražen kronicitet na biopsiji bili su pokazatelji povoljnog ishoda bubrežne funkcije. Bolesnici koji 
su dobro odgovorili na terapiju imali su najvišu početnu i najnižu završnu 24-satnu proteinuriju. najviša završna 24-satna 
proteinurija zabilježena je u bolesnika ovisnih o dijalizi. Kumulativno jednogogodišnje i dvogodišnje preživljavanje bole-
snika je bilo 64% i 50%, a bubrega 64% i 38%.
Ključne riječi: Antitijela, antineutrofilna citoplazmatska; ANCA-pozitivni vaskulitis; Bubrežne bolesti; Glomerulonefritis

